BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
일요일, 9월 20

Adicet Bio Inc

ACETNASDAQ
Trade with Public
Trade with Public
$9.18
0.171.89%
가까이에: Sep 18, 5:00 PM EST
$9.18
N/A
시간외: Sep 18, 4:00 PM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Adicet Bio Financials

Adicet Bio (ACET) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Adicet Bio Q2 EPS $(1.99) Beats $(2.03) Estimate

Adicet Bio (NASDAQ:ACET) reported quarterly losses of $(1.99) per share which beat the analyst consensus estimate of $(2.03) by 1.97 percent. This is a 63.42 percent increase over losses of $(5.44) per share from the
Benzinga Newsdesk

PRO
Adicet Bio Q1 EPS $(1.88) Beats $(3.21) Estimate

Adicet Bio (NASDAQ:ACET) reported quarterly losses of $(1.88) per share which beat the analyst consensus estimate of $(3.21) by 41.43 percent. This is a 62.1 percent increase over losses of $(4.96) per share from the
Benzinga Newsdesk

PRO
Adicet Bio Q4 EPS $(2.94) Beats $(3.10) Estimate

Adicet Bio (NASDAQ:ACET) reported quarterly losses of $(2.94) per share which beat the analyst consensus estimate of $(3.10) by 5.04 percent. This is a 42.58 percent increase over losses of $(5.12) per share from the
Benzinga Newsdesk

PRO
Adicet Bio Q3 EPS $(0.29) Beats $(0.30) Estimate

Benzinga Newsdesk

PRO
Adicet Bio Q2 EPS $(0.34) Misses $(0.30) Estimate

Adicet Bio (NASDAQ:ACET) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.30) by 12.58 percent. This is a 3.03 percent decrease over losses of $(0.33) per share from the
Benzinga Newsdesk

PRO
Adicet Bio Q1 EPS $(0.31) Beats $(0.34) Estimate

Adicet Bio (NASDAQ:ACET) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.34) by 8.82 percent. This is a 11.43 percent increase over losses of $(0.35) per share from the
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

BenzingaBenzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved